About PolyPeptide
PolyPeptide is a company based in Baar (Switzerland) founded in 1952. The company has 1,360 employees. PolyPeptide offers products and services including Custom Research Grade Peptides, Radiolabeled Peptide, Generic Peptides, and Oligos. PolyPeptide operates in a competitive market with competitors including Enzene Biosciences, Hybio Pharmaceutical, AmbioPharm, Ocelot Bio and Aperiam Bio, among others.
- Headquarter Baar, Switzerland
- Employees 1,360
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website polypeptide.com
- Social LinkedIn X Facebook YouTube
- Legal Name Polypeptide Group Ag
- Annual Revenue₹94.10 Cr
FY 2025 · +34% YoY
- Net Profit₹1.98 Cr
FY 2025 · 2% margin
- EBITDA₹18.61 Cr
FY 2025 · 20% margin
- Employee Count1,360
Associated legal entities of PolyPeptide
PolyPeptide operates through Polypeptide Laboratories Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Polypeptide Laboratories Private Limited CIN U51397MH2001PTC130734 | Active | 06 Feb 2001 | Ambernath, Maharashtra | ₹94.1 Cr | 108 | 4 | View details |
Board of directors of Polypeptide Laboratories Private Limited (PolyPeptide)
Polypeptide Laboratories Private Limited is the primary company behind PolyPeptide. The board of Polypeptide Laboratories Private Limited currently have 3 directors; the longest-serving is Ashok Dattatraya Alate, appointed in 2001. 11 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Ashok Dattatraya Alate DIN 00491315 | Director | 06 Feb 2001 | 25 yrs 8 mo | Polypeptide Laboratories Private Limited |
| Jens Fricke DIN 10060823 | Director | 01 Mar 2023 | 3 yrs 7 mo | Polypeptide Laboratories Private Limited |
| Juan Jose Gonzalez Casanova DIN 10214229 | Director | 28 Jun 2023 | 3 yrs 3 mo | Polypeptide Laboratories Private Limited |
People of PolyPeptide
58 people are tracked at PolyPeptide (14 in leadership, 4 in board & advisors, 40 in team); the tracked headcount is 1,360.
| Name | Role | Group |
|---|---|---|
| CEO | Leadership | |
Christina Del Vecchio | Chief Legal Officer | Leadership |
Megan Lipnick | Head Of Quality Assurance | Leadership |
Elena Grkovska | HR Business Partner | Leadership |
Monika Casanova | Chief Human Resources Officer | Leadership |
Jørgen Andersen | Head Of Hr, Sweden | Leadership |
Seema Pujari | Head Of Human Resources | Leadership |
Krister Svärd | Chief Information Security Officer | Leadership |
Inas Khedher | Head Of Operations Controlling | Leadership |
Viveka Persson | Head Of Global Finance Transformation | Leadership |
Mark Miles | Quality Assurance Director | Leadership |
Aurore Palicot | Head Of Quality Unit | Leadership |
Marco Henseler | Director Global Accounting And Consolidation | Leadership |
Joel Espejo | US Head - Human Resources | Leadership |
Erik Schropp | Board Member | Board & advisors |
Philippe Weber | Independent Member | Board & advisors |
Patrick Aebischer | Vice Chairman & Lead Independent Director | Board & advisors |
Peter Wilden | Chairman | Board & advisors |
Rada Chanmugathas | Environmental Health And Safety Manager | Team |
Louise Bengtsson | Validation Specialist | Team |
38 more people are available in the full profile.
Complete people profiles for PolyPeptide
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of PolyPeptide
PolyPeptide is a publicly listed company on the SIX with ticker symbol PPGN in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date12 Nov 2021
- Listed onLSE: 0AAJ
- Listed entityPolyPeptide Group AG
- Exchange sectorHealth technology
- ISINCH1110760852
- Share price39.55 CHF (+0.38% on the day) · 2026-05-11
- Market capitalisation1,301,431,300.00 CHF
- Price to earnings109.1
- EPS (diluted, trailing year)-0.61 CHF
- Volume (last session)36,185
- Analyst consensusBuy
Products & Services of PolyPeptide
PolyPeptide offers a comprehensive portfolio of products and services, including Custom Research Grade Peptides, Radiolabeled Peptide, Generic Peptides, and Oligos.
Services for custom peptide research and development purposes.
Manufacturing of radiolabeled peptides for pharmaceutical applications.
Production of generic peptides for biotech and research needs.
Custom synthesis of oligos for scientific and medical use.
Apps and channels of PolyPeptide
its YouTube channel PolyPeptide Group has 696 subscribers and 30 videos.
Financials of PolyPeptide
Figures of Polypeptide Laboratories Private Limited, the primary company behind PolyPeptide, for FY 2025. Revenue was ₹94.10 Cr (+34% year on year). Net profit was ₹1.98 Cr (2% margin). EBITDA was ₹18.61 Cr (20% margin). Revenue has grown at a compounded annual rate of +16% over three years and +20% over five years.
- ₹94.10 CrRevenue · FY 2025 · +34% YoY
- ₹1.98 CrNet profit · 2% margin
- ₹18.61 CrEBITDA · 20% margin
- ₹60.38 CrPaid-up capital
- 108Employees (provident fund records)
- +16%Revenue CAGR, 3 years
- +20%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 364.9M CHF | -19.8M CHF | 41.4M CHF |
| 2024 | 320.8M CHF | -18.6M CHF | 22.3M CHF |
| 2023 | 311.3M CHF | -50.0M CHF | -10.2M CHF |
| 2022 | 282.0M CHF | 7.8M CHF | 36.3M CHF |
| 2021 | 304.9M CHF | 51.1M CHF | 87.3M CHF |
Balance sheet, profit and loss, cash flow and ratios of Polypeptide Laboratories Private Limited are on its company page.
Detailed financial statements for PolyPeptide
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of PolyPeptide
PolyPeptide operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Enzene Biosciences, Hybio Pharmaceutical, AmbioPharm, Ocelot Bio and Aperiam Bio, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| enzene.com | 2006 | Pune, India | $50.0M | 10 | Company specializing in development of Biosimilars | |
| hybio.com.cn | 1998 | Shenzhen, China | $15.0M | – | Polypeptide drugs and APIs are developed and manufactured. | |
| ambiopharm.com | 2006 | North Augusta, United States | $24.0M | 186 | CDMO and analytical services for peptide development are provided. | |
| ocelotbio.com | 2020 | San Diego, United States | $36.0M | – | Ocelot Bio is a CDMO specializing in peptide manufacturing services. | |
| aperiambio.com | 2019 | United States | $13.0M | – | Industrial and therapeutic proteins are manufactured by Aperiam Bio. | |
| maruho.co.jp | 1915 | Osaka, Japan | – | – | Conducts R&D and manufactures ethical drugs for healthcare applications. | |
| micot.cn | 2007 | China | $72.2M | – | Drug R&D services for cardiovascular and metabolic diseases are provided. | |
| vivitide.com | 1983 | Gardner, United States | – | 94 | Drug development services for neoantigen peptides and antibodies are provided. | |
| ramedapharma.com | 1994 | Giza, Egypt | – | 2 | Developer and manufacturer of generic pharmaceuticals, nutraceuticals, food supplements and veterinary products |
Detailed competitors of PolyPeptide
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Polypeptide
Complete news archive for PolyPeptide
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Similar companies to PolyPeptide
10 companies that operate in the same segment as PolyPeptide (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 255.15 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Frequently Asked Questions about PolyPeptide
PolyPeptide was founded in 1952.
PolyPeptide is headquartered in Baar, Switzerland. It is registered at Baar, Zug, Switzerland.
Juan Jose Gonzalez is the current CEO of PolyPeptide.
PolyPeptide has 1,360 employees.
The primary company behind PolyPeptide, Polypeptide Laboratories Private Limited, reported revenue of ₹94.10 Cr for FY 2025, up 34% year on year.
PolyPeptide Labs is a CMO manufacturing proprietary (generally approved drug substances), GMP grade (for clinical trials) and non-GMP grade (small scale custom synthesis) - peptides for the pharmaceutical, cosmetic, biotechnology and veterinary markets. Using their synthetic technologies and methodologies, they manufacture peptides up to 80 amino acids in length and in quantities ranging from milligramgram to multi-10kg quantities. Depending on the nature and quantity of the peptide needed, a solid phase, a classical liquid phase, or a hybrid approach is developed for manufacturing. They claim to manufacture over one-third of all approved peptide drug substances (22 of 62 approved products worldwide) accounting for over 25 of the sales of outsourced peptide therapeutics worldwide.
PolyPeptide's top competitors include Enzene Biosciences, Hybio Pharmaceutical and AmbioPharm.
PolyPeptide offers Custom Research Grade Peptides, Radiolabeled Peptide, Generic Peptides, and Oligos.
Yes, PolyPeptide is publicly traded on SIX under the ticker symbol PPGN.
PolyPeptide operates through Polypeptide Laboratories Private Limited.
The legal entities of PolyPeptide currently have 4 directors, including Juan Jose Gonzalez Casanova, Navleen Kaur Surinder Anand, Jens Fricke and others.